trending Market Intelligence /marketintelligence/en/news-insights/trending/tt5uEMlk8jpmQ_tGgz3tDg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Consun Pharmaceutical considering spin off of traditional medicines unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Consun Pharmaceutical considering spin off of traditional medicines unit

Consun Pharmaceutical Group Ltd. is considering a potential spin off and listing of its indirect, non-wholly owned unit Guangxi Yulin Pharmaceutical Group Co. Ltd. and its subsidiaries.

Yulin Pharmaceutical develops and sells traditional Chinese and natural medicines. It has not yet submitted any listing application to the China Securities Regulatory Commission, the relevant stock exchange in China, or the Hong Kong Stock Exchange, Consun said in a release.

A financial adviser for the potential spin off and listing was appointed by Consun Pharmaceutical on Oct. 18, it said.